Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

An Exploratory Study to Evaluate the Tolerability and Safety of MWAV201 in Subjects With Wilson Disease

NCTID NCT06663878 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Wilson Disease
Disease Ontology Term DOID:893
Compound Name MWAV201
Sponsor Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Funder Type Other
Recruitment Status
Not yet recruiting
Enrollment Count 9
Results Posted Not Available

Therapy Information

Target Gene/Variant Undisclosed
Therapy Type Undisclosed
Therapy Route Undisclosed
Mechanism of Action Undisclosed
Route of Administration Intravenous
Drug Product Type Undisclosed
Target Tissue/Cell
Delivery System Undisclosed
Vector Type undisclosed
Editor Type undisclosed
Dose 1 Undisclosed
Dose 2
Dose 3
Dose 4
Dose 5

Study Record Dates

Current Stage Na
Submit Date 2024-10-10
Completion Date 2031-05
Last Update 2024-10-29

Participation Criteria

Eligible Age 18 Years - 65 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL

Locations

No.of Trial Sites 1
Locations China

Regulatory Information

Has US IND False
FDA Designations
Recent Updates

Resources/Links

Resources/Links

No External Links Available.